In addition to identifying SLP as an unexpected TLR4 agonist, we revealed for the first time that inhibiting SLP-mediated TLR2/4 activation in experimental endophthalmitis could reduce disease severity. This evidence concerns the gene TLR2 and endophthalmitis.